These Analysts Slash Their Forecasts On EyePoint
EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.
EyePoint's new eye-medicine test didn't hit its main goal, but showed some positive signs in smaller goals. When companies miss big targets, analysts often lower their guesses about future success, which is worth noticing when watching this stock.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.